/u/Cool_Excitement1584's posts in /r/Scholar

Year:

Only show posts with narrations

[Article] Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment

1 upvotes

Mark as read: Add to a list

[Article] New Evidence on Diclofenac: Implications for Cardiovascular Safety

1 upvotes

Mark as read: Add to a list

[Article] Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

1 upvotes

Mark as read: Add to a list

[Article] Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

1 upvotes

Mark as read: Add to a list

[Article] New Antipsychotic Medications in the Last Decade

1 upvotes

Mark as read: Add to a list

[Article] Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

1 upvotes

Mark as read: Add to a list

[Article] Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia

1 upvotes

Mark as read: Add to a list

[Article] Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment

1 upvotes

Mark as read: Add to a list

[Article] Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review

1 upvotes

Mark as read: Add to a list

Title	Upvotes	Mark as read	Favorited	Rating	Add to a list
[Article] Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment	1
[Article] New Evidence on Diclofenac: Implications for Cardiovascular Safety	1
[Article] Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial	1
[Article] Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study	1
[Article] New Antipsychotic Medications in the Last Decade	1
[Article] Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia	1
[Article] Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	1
[Article] Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment	1
[Article] Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review	1